Cargando…

Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience

SIMPLE SUMMARY: Neuroendocrine neoplasms (NENs) of unknown primary (NEN-UPs) encompass a small group within all diagnosed NENs. As a result, diagnostic work-up and the therapy algorithm are not standardized. In this study we consecutively analyzed a cohort of 113 patients, initially diagnosed as NEN...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Moritz, Hinterleitner, Clemens, Singer, Stephan, Lauer, Ulrich M., Zender, Lars, Hinterleitner, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486951/
https://www.ncbi.nlm.nih.gov/pubmed/37686593
http://dx.doi.org/10.3390/cancers15174316
_version_ 1785103119023079424
author Schmidt, Moritz
Hinterleitner, Clemens
Singer, Stephan
Lauer, Ulrich M.
Zender, Lars
Hinterleitner, Martina
author_facet Schmidt, Moritz
Hinterleitner, Clemens
Singer, Stephan
Lauer, Ulrich M.
Zender, Lars
Hinterleitner, Martina
author_sort Schmidt, Moritz
collection PubMed
description SIMPLE SUMMARY: Neuroendocrine neoplasms (NENs) of unknown primary (NEN-UPs) encompass a small group within all diagnosed NENs. As a result, diagnostic work-up and the therapy algorithm are not standardized. In this study we consecutively analyzed a cohort of 113 patients, initially diagnosed as NEN-UPs. After extensive diagnostic work-up, in 11.5% (13 patients) a primary tumor site could be identified. Our study revealed that an extensive diagnostic work-up, in particular somatostatin receptor (SSTR)-PET, is associated with a better clinical outcome. Our study proposes that a detailed diagnostic investigation and the identification of a primary tumor site can provide the rationale for a tumor-specific therapy, contributing to a prolonged survival in NEN-UPs. ABSTRACT: Neuroendocrine neoplasms (NENs) represent a rare and heterogenous group of tumors with predominantly gastroenteropancreatic or pulmonary origin. Despite numerous diagnostic efforts, the primary tumor site remains unknown in up to 20% of the patients diagnosed with NEN. In this subgroup of NEN patients, a standard diagnostic algorithm has not yet been integrated into clinical routine. Of note, an undetermined primary tumor site in NENs is associated with an impaired clinical outcome by at least “formally” limiting treatment options exclusively approved for NENs of a certain histological origin. In this retrospective study, a patient cohort of 113 patients initially diagnosed with NEN of unknown primary (NEN-UP) was analyzed. In 13 patients (11.5%) a primary tumor site could be identified subsequently, amongst others, by performing somatostatin receptor (SSTR)-PET-based imaging, which was irrespective of the initial clinical or demographic features. Diagnostic work-up and therapeutic regimens did not differ significantly between patients with an identified or unidentified primary tumor site; only a detailed immunohistochemical assessment providing additional information on the tumor origin proved to be significantly associated with the detection of a primary tumor site. Our study revealed that a profound diagnostic work-up, particularly including SSTR-PET-based imaging, leads to additional treatment options, finally resulting in significantly improved clinical outcomes for patients with NEN-UPs.
format Online
Article
Text
id pubmed-10486951
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104869512023-09-09 Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience Schmidt, Moritz Hinterleitner, Clemens Singer, Stephan Lauer, Ulrich M. Zender, Lars Hinterleitner, Martina Cancers (Basel) Article SIMPLE SUMMARY: Neuroendocrine neoplasms (NENs) of unknown primary (NEN-UPs) encompass a small group within all diagnosed NENs. As a result, diagnostic work-up and the therapy algorithm are not standardized. In this study we consecutively analyzed a cohort of 113 patients, initially diagnosed as NEN-UPs. After extensive diagnostic work-up, in 11.5% (13 patients) a primary tumor site could be identified. Our study revealed that an extensive diagnostic work-up, in particular somatostatin receptor (SSTR)-PET, is associated with a better clinical outcome. Our study proposes that a detailed diagnostic investigation and the identification of a primary tumor site can provide the rationale for a tumor-specific therapy, contributing to a prolonged survival in NEN-UPs. ABSTRACT: Neuroendocrine neoplasms (NENs) represent a rare and heterogenous group of tumors with predominantly gastroenteropancreatic or pulmonary origin. Despite numerous diagnostic efforts, the primary tumor site remains unknown in up to 20% of the patients diagnosed with NEN. In this subgroup of NEN patients, a standard diagnostic algorithm has not yet been integrated into clinical routine. Of note, an undetermined primary tumor site in NENs is associated with an impaired clinical outcome by at least “formally” limiting treatment options exclusively approved for NENs of a certain histological origin. In this retrospective study, a patient cohort of 113 patients initially diagnosed with NEN of unknown primary (NEN-UP) was analyzed. In 13 patients (11.5%) a primary tumor site could be identified subsequently, amongst others, by performing somatostatin receptor (SSTR)-PET-based imaging, which was irrespective of the initial clinical or demographic features. Diagnostic work-up and therapeutic regimens did not differ significantly between patients with an identified or unidentified primary tumor site; only a detailed immunohistochemical assessment providing additional information on the tumor origin proved to be significantly associated with the detection of a primary tumor site. Our study revealed that a profound diagnostic work-up, particularly including SSTR-PET-based imaging, leads to additional treatment options, finally resulting in significantly improved clinical outcomes for patients with NEN-UPs. MDPI 2023-08-29 /pmc/articles/PMC10486951/ /pubmed/37686593 http://dx.doi.org/10.3390/cancers15174316 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schmidt, Moritz
Hinterleitner, Clemens
Singer, Stephan
Lauer, Ulrich M.
Zender, Lars
Hinterleitner, Martina
Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience
title Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience
title_full Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience
title_fullStr Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience
title_full_unstemmed Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience
title_short Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience
title_sort diagnostic approaches for neuroendocrine neoplasms of unknown primary (nen-ups) and their prognostic relevance—a retrospective, long-term single-center experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486951/
https://www.ncbi.nlm.nih.gov/pubmed/37686593
http://dx.doi.org/10.3390/cancers15174316
work_keys_str_mv AT schmidtmoritz diagnosticapproachesforneuroendocrineneoplasmsofunknownprimarynenupsandtheirprognosticrelevancearetrospectivelongtermsinglecenterexperience
AT hinterleitnerclemens diagnosticapproachesforneuroendocrineneoplasmsofunknownprimarynenupsandtheirprognosticrelevancearetrospectivelongtermsinglecenterexperience
AT singerstephan diagnosticapproachesforneuroendocrineneoplasmsofunknownprimarynenupsandtheirprognosticrelevancearetrospectivelongtermsinglecenterexperience
AT lauerulrichm diagnosticapproachesforneuroendocrineneoplasmsofunknownprimarynenupsandtheirprognosticrelevancearetrospectivelongtermsinglecenterexperience
AT zenderlars diagnosticapproachesforneuroendocrineneoplasmsofunknownprimarynenupsandtheirprognosticrelevancearetrospectivelongtermsinglecenterexperience
AT hinterleitnermartina diagnosticapproachesforneuroendocrineneoplasmsofunknownprimarynenupsandtheirprognosticrelevancearetrospectivelongtermsinglecenterexperience